COMMUNIQUÉS West-GlobeNewswire

LeMaitre to Present at the Bank of America Securities 2025 Healthcare Conference
05/05/2025
BURLINGTON, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that David Roberts, President, will present at the Bank of America Securities 2025 Healthcare Conference on [...]
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05/05/2025
MALVERN, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life [...]
DBV Technologies to Participate in the Citizens JMP Life Sciences Conference
05/05/2025
Châtillon, France, May 5, 2025 DBV Technologies to Participate in the Citizens JMP Life Sciences Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage [...]
DBV Technologies participera à la conférence Citizens JMP Life Sciences
05/05/2025
Châtillon, France, le 5 mai (22 :30 CEST) 2025 DBV Technologies participera à la conférence Citizens JMP Life Sciences DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market : DBVT), société [...]
Certara Reports First Quarter 2025 Financial Results
05/05/2025
Reiterates Full Year 2025 Financial Guidance RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the [...]
Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update
05/05/2025
Announced rosnilimab, a depleter and agonist targeting PD-1+ T cells, achieved positive results in Phase 2b rheumatoid arthritis (RA) trial; to present updated clinical and translational data in the first week of June [...]
SI-BONE, Inc. Reports Financial Results for the First Quarter 2025 and Updates 2025 Guidance
05/05/2025
Achieved ~25% worldwide revenue growth and positive adjusted EBITDA First Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $47.3 million, representing growth of 24.9 [...]
Castle Biosciences Reports First Quarter 2025 Results
05/05/2025
Q 1 2025 revenue increased 21% over Q 1 2024 to $88 million Q 1 2025 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, DecisionDx ® -SCC, TissueCypher ® ) increased 33% over Q 1 2024 Raising full- [...]
Context Therapeutics Announces Chief Medical Officer Transition
05/05/2025
Board Member Dr. Karen Smith to serve as Interim Chief Medical Officer PHILADELPHIA, May 05, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical [...]
Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates
05/05/2025
Cash runway extended into 2029 Initiation of Phase 3 ReDiscover-2 trial on track for mid-2025 Initiated Phase 1 RLY-2608 vascular malformations clinical trial in Q1 Extended cash runway expected to fully fund the [...]
Castle Biosciences to Acquire Previse
05/05/2025
Expected to complement Castle’s current gastroenterology franchise Adds methylation technology developed at the Johns Hopkins University School of Medicine and additional technologies in development FRIENDSWOOD, Texas, [...]
FibroGen to Report First Quarter 2025 Financial Results
05/05/2025
SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2025 financial results on Monday, May 12 after the markets close. FibroGen will also conduct a conference call on [...]
Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights
05/05/2025
Company Announces Strategic Realignment to Focus on Core Programs and Extend Cash Runway Icovamenib progressing toward the next phase of clinical development in insulin deficient type 2 diabetes patients and patients [...]
Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025
05/05/2025
RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD [...]
ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates
05/05/2025
Announced focused registrational clinical development plans for lead programs, extended cash runway, and accelerated/augmented corporate milestones Presented preclinical data supporting potential best-in-class profile [...]
uniQure to Announce First Quarter 2025 Financial Results
05/05/2025
~ uniQure to host inaugural earnings call on Friday, May 9, 2025 at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 05, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy [...]
Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates
05/05/2025
- Progression-free survival data from more than 30 patients with first line pancreatic cancer in the ongoing Phase 2a trial of IMM-1-104 trial planned for announcement in 2Q’25 - - Reported positive data from the [...]
Inspire Medical Systems, Inc. Announces First Quarter 2025 Financial Results and Updates 2025 Outlook
05/05/2025
Inspire Reports Year-over-Year Revenue Growth of 23% and Earnings per Share of $0.10 in the First Quarter Inspire Reports Year-over-Year Revenue Growth of 23% and Earnings per Share of $0.10 in the First Quarter [...]
Xenon to Report Q1 2025 Financial Results on May 12, 2025
05/05/2025
VANCOUVER, British Columbia and BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering [...]

Pages